
    
      To evaluate the objective response rate of oxaliplatin combined with 5-FU in patients with
      recurrent or metastatic head and neck cancer.

      To assess the safety profile of these treatment regimen. To evaluate the duration of response
      of oxaliplatin/5-FU.
    
  